US life sciences information service BioSpace reports on the resultsof two phase III trials evaluating Miraxion (semisynthetic ethyl-EPAderivative) in treating Huntington’s disease, which have been releasedby Amarin Corporation. In both double-blind, placebo-controlledstudies, patients with the disease were randomised to receive eitherplacebo or Miraxion (1g bd) for six months. The primary endpoint of thetrials was a change in the Total Motor Score 4 component of the UnifiedHuntington’s Disease Rating Scale; secondary endpoints includedcognition and Total Functional Capacity outcomes. No statisticallysignificant difference was found between the placebo and Miraxiongroups in any of the endpoints studied.
National Electronic Library for Medicines 25/4/2007